- Home
- IDT vs GLUE Comparison
IDT vs GLUE Comparison
Compare IDT & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IDT | GLUE |
|---|---|---|
| Founded | 1990 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IDT | GLUE |
|---|---|---|
| Price | $65.86 | $16.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $80.00 | $32.00 |
| AVG Volume (30 Days) | 170.4K | ★ 1.4M |
| Earning Date | 06-04-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.55% | N/A |
| EPS Growth | ★ 18.50 | N/A |
| EPS | ★ 2.59 | N/A |
| Revenue | ★ $1,231,495,000.00 | $123,672,000.00 |
| Revenue This Year | $4.34 | N/A |
| Revenue Next Year | N/A | $2.45 |
| P/E Ratio | ★ $25.28 | $72.42 |
| Revenue Growth | 2.13 | ★ 63.54 |
| 52 Week Low | $45.72 | $4.30 |
| 52 Week High | $69.15 | $25.77 |
Technical Indicators
Market Signals| Indicator | IDT | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 60.22 | 33.10 |
| Support Level | $50.83 | $14.52 |
| Resistance Level | $68.31 | $17.40 |
| Average True Range (ATR) | 1.80 | 1.11 |
| MACD | -0.39 | -0.41 |
| Stochastic Oscillator | 44.56 | 13.50 |
Price Performance
Historical ComparisonAbout IDT IDT Corporation Class B
IDT Corp is a multinational holding company. It operates in the telecommunications and payment industries. It has four reportable business segments, Fintech, National Retail Solutions; net2phone and Traditional Communications, The Fintech segment is comprised of National Retail Solutions (NRS), an operator of a nationwide point of sale (POS) network providing payment processing, digital advertising, transaction data, and ancillary services, and BOSS Money, a provider of international money remittance and related value/payment transfer services. The net2phone segment provides unified cloud communications and telephony services to business customers.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).